Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Dr. Reddy's Laboratories Ltd.
Change Company   
BSE Code 500124
ISIN Demat INE089A01031
Book Value 379.50
NSE Code DRREDDY
Dividend Yield % 0.63
Market Cap 1052815.36
P/E 15.27
EPS 82.59
Face Value 1  
20-Aug-2025 Dr Reddys Laboratories informs about allotment of...
20-Aug-2025 Dr. Reddy’s Laboratories informs about newspaper ...
11-Aug-2025 Dr. Reddy's Laboratories gets EIR for API manufac...
11-Aug-2025 Dr. Reddy's Laboratories gains after getting EIR ...
26-Jul-2025 Dr. Reddy's makes investment of Rs 565.40 crore i...
24-Jul-2025 Dr Reddy's Laboratories reports marginal rise in ...
24-Jul-2025 Dr Reddy's Laboratories moves higher on reporting...
22-Jul-2025 Dr. Reddy's gets EIR for API manufacturing facili...
21-Jul-2025 USFDA completes GMP and Pre-Approval Inspection a...
15-Jul-2025 Dr Reddys Laboratories informs about press release
02-Jul-2025 Dr. Reddy’s Laboratories informs about newspaper ...
30-Jun-2025 Dr. Reddy’s Laboratories submits BRSR
05-Jun-2025 Dr. Reddy's Laboratories, Alvotech enter into lic...
05-Jun-2025 Dr. Reddy’s Laboratories informs about press rel...
05-Jun-2025 Dr. Reddy's Laboratories soars on entering into l...
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.